News

Rocket Pharmaceuticals plans to quickly resume the phase 1 trial and commence dosing in their new, low-dose, pediatric cohort in Q3 2021.

The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Targeted CRISPR therapy has potential in treating inherited retinal diseases.

The professor from the University of Texas Anderson Cancer Center discussed challenges surrounding CAR T-cell therapy for the treatment of follicular lymphoma and other lymphomas.

The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.

A phase 1/2 study evaluating Vivet Therapeutic’s VTX-801 is set to initiate in August 2021.

Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed the company’s work in ophthalmic diseases.

David G. Maloney, MD, PhD, covered the importance of standardized criteria in managing CRS and ICANS with CAR T therapy.

The chief executive and chief medical officer of Celyad Oncology discussed the advantages of allogeneic CAR T therapies over autologous ones.

The World Federation of Hemophilia’s registry will include long-term safety and efficacy data in people with hemophilia treated with gene therapies.

The professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.

Experts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.

Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the company’s gene therapy pipeline, including their lead program ETX101.

Bluebird Bio’s latest clinical hold follows another report of MDS in a treated patient.

Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed factors to consider in selecting CAR T-cell therapies.

Noa Biran, MD, discusses exciting new agents in the field that may fulfill unmet patient needs.

The Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Basking Ridge discussed patient factors to consider when selecting treatment in R/R MCL.

The non-randomized, open-label trial of AIC100 is currently recruiting patients at the Weill Cornell Medical College in in New York.

CAR T-cell therapy showed promising results in acute myeloid leukemia at ASCO 2021.

The inaugural leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, University of Miami discussed exciting novel therapeutic approaches in multiple myeloma.

Jan Philipp Bewersdorf, MD, hospital resident at Yale University School of Medicine discussed the safety and efficacy of allogeneic hematopoietic stem cell transplant in myelofibrosis.

Sam Wadsworth, PhD, chief scientific officer of Ultragenyx Pharmaceuticals, discussed the company’s platform for efficiently producing AAV vectors.

No concerning effects to liver health were observed in the phase 1/2a study.

The president and chief operating officer of Agenus discussed the cell therapies the company is developing for the treatment of multiple myeloma.

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed emerging CAR T-cell therapies in hematologic malignancies.

Clinical trials for both AGTC-401 and AGTC-402 show promising results.

The company announced plans to initiate the STEER study of intrathecal OAV-101 for older patients with SMA type 2.